(Q37828321)

24 August 2017

1 reference

title

Therapeutic targets in liver fibrosis (English)

1 reference

24 August 2017

author

Jonathan A Fallowfield

1

object named as

Jonathan A. Fallowfield

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21233278

22 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21233278

22 November 2024

publication date

13 January 2011

1 reference

full work available at URL

24 August 2017

https://www.physiology.org/doi/pdf/10.1152/ajpgi.00451.2010

1 reference

https://api.crossref.org/works/10.1152/AJPGI.00451.2010

American Journal of Physiology - Gastrointestinal and Liver Physiology

22 November 2024

published in

1 reference

24 August 2017

volume

300

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

G709-15

1 reference

A pilot study in patients with established advanced liver fibrosis using pirfenidone

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Identifying off-target effects and hidden phenotypes of drugs in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Current and future anti-fibrotic therapies for chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Antifibrotic therapies--emerging biomarkers as treatment end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00451.2010

Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis

21 January 2018

13

1 reference

https://api.crossref.org/works/10.1152/AJPGI.00451.2010

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

22 November 2024

26

1 reference

https://api.crossref.org/works/10.1152/AJPGI.00451.2010

Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients

22 November 2024

27

1 reference

https://api.crossref.org/works/10.1152/AJPGI.00451.2010

22 November 2024

Identifiers

1 reference

24 August 2017

1 reference